{"title":"New Trends Approved in Management of Dyslipidaemia","authors":"Abdulaziz Aboshahba","doi":"10.19080/jocct.2019.14.555894","DOIUrl":null,"url":null,"abstract":"Hypercholesterolemia increases the risk of atherosclerotic cardiovascular disease and is incompletely reversed by statin therapy alone in many patients. Familial hypercholesterolemia (FH) is a common genetic cause of premature cardiovascular disease (CVD). So, most of efforts and directions focused on new therapies as PCSK9 gene was identified in the past decade as a potential therapeutic target for the management of patients with hypercholesterolemia which monoclonal antibodies, Lomitapide, Mipomersen and other therapies hoping to reduce risk of hypercholesterolemia. The novel therapies are aiming for better lipid-lowering effects, fewer side effects and improved clinical outcomes.","PeriodicalId":73635,"journal":{"name":"Journal of cardiology & cardiovascular therapy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cardiology & cardiovascular therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19080/jocct.2019.14.555894","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Hypercholesterolemia increases the risk of atherosclerotic cardiovascular disease and is incompletely reversed by statin therapy alone in many patients. Familial hypercholesterolemia (FH) is a common genetic cause of premature cardiovascular disease (CVD). So, most of efforts and directions focused on new therapies as PCSK9 gene was identified in the past decade as a potential therapeutic target for the management of patients with hypercholesterolemia which monoclonal antibodies, Lomitapide, Mipomersen and other therapies hoping to reduce risk of hypercholesterolemia. The novel therapies are aiming for better lipid-lowering effects, fewer side effects and improved clinical outcomes.